EMD 2.22% 4.6¢ emyria limited

general talk, page-237

  1. 285 Posts.
    lightbulb Created with Sketch. 56

    "Emyria managing director Michael Winlo said the big opportunity for his company was to become a leader in the delivery of MDMA-assisted therapy.


    Emyria in early October dosed its first patient in its MDMA-assisted therapy trial for post-traumatic stress disorder, believed to be a first for a private specialist clinic operating distinctively from academic centres and public and private hospitals.

    It follows a decision by the Therapeutic Goods Administration in February allowing medicines containing psilocybin — a psychedelic compound found in magic mushrooms — and MDMA to be prescribed to patients by authorised psychiatrists from July 1.

    “Australia was a world leader in re-scheduling these medications, they moved at least a year ahead of the rest of the world,” Dr Winlo said.

    “By establishing a leadership position we see an opportunity to contribute to the global effort to develop better treatments for mental health disease.”

    In 2024, Dr Winlo hopes to launch the MDMA-assisted therapy program outside the clinical trial and get the engagement of major health players."


 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
(20min delay)
Last
4.6¢
Change
0.001(2.22%)
Mkt cap ! $18.81M
Open High Low Value Volume
4.7¢ 4.7¢ 4.5¢ $4.93K 107.0K

Buyers (Bids)

No. Vol. Price($)
2 26500 4.4¢
 

Sellers (Offers)

Price($) Vol. No.
4.6¢ 6875 1
View Market Depth
Last trade - 15.36pm 19/07/2024 (20 minute delay) ?
EMD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.